Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C10H8O3 |
| Molecular Weight | 176.1687 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1=CC(=O)OC2=C1C=CC(O)=C2
InChI
InChIKey=HSHNITRMYYLLCV-UHFFFAOYSA-N
InChI=1S/C10H8O3/c1-6-4-10(12)13-9-5-7(11)2-3-8(6)9/h2-5,11H,1H3
| Molecular Formula | C10H8O3 |
| Molecular Weight | 176.1687 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
DescriptionCurator's Comment: description was created based on several sources, including
http://www.ncbi.nlm.nih.gov/pubmed/25852691
Curator's Comment: description was created based on several sources, including
http://www.ncbi.nlm.nih.gov/pubmed/25852691
Hymecromone (4-methylumbelliferone) is already approved drug in Europe and Asia where it is used to treat biliary spasm. It is used as choleretic and antispasmodic drugs and as a standard for the fluorometric determination of enzyme activity. The concomitant administration of Hymecromone with products, containing metoclopramide, leads to mutual decrease of their action. Due to a danger of diarrhea with subsequent hypokalemia, Hymecromone should be applied with caution to patients on cardiac glycosides therapy (in these cases the sensitivity to them is increased). Hymecromone can be administered simultaneously with otherspasmolytics and analgesics. Very rare allergic reactions, itching, erythema, rashes; diarrhea which normally disappears by reduction of dose or discontinuance of therapy.
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Hymecromone in the treatment of motor disorders of the bile ducts: a multicenter, double-blind, placebo-controlled clinical study. | 2001 |
|
| New lanthanide complexes of 4-methyl-7-hydroxycoumarin and their pharmacological activity. | 2001 Apr |
|
| Determination of UDP-glucuronosyltransferase UGT1A6 activity in human and rat liver microsomes by HPLC with UV detection. | 2001 Apr |
|
| Cloning and characterization of a bacterial cell-bound type B carboxylesterase from Bacillus sp. BP-7. | 2001 Apr |
|
| Leishmania donovani: expression and characterization of Escherichia coli-expressed recombinant chitinase LdCHT1. | 2001 Dec |
|
| Improved method for the fluorimetric detection of beta-D-galactosidase in water. | 2001 Mar |
|
| High beta-galactosidase and ganglioside GM1 levels in the human parotid gland. | 2001 Nov |
|
| A fluorogenic assay using pressure-driven flow on a microchip. | 2001 Oct |
|
| A beta-glucosidase/xylosidase from the phytopathogenic oomycete, Phytophthora infestans. | 2002 Apr |
|
| Protection against damaged DNA in the single cell by polyphenols. | 2002 Dec |
|
| A colorimetric and fluorometric microplate assay for the detection of microcystin-LR in drinking water without preconcentration. | 2002 Nov |
|
| Effects of bergamottin on human and monkey drug-metabolizing enzymes in primary cultured hepatocytes. | 2002 Sep |
|
| [A case of successful use of odeston in the diagnostics and treatment of biliary dysfunctional disorders]. | 2003 Dec |
|
| Verapamil regulates activity and mRNA-expression of human beta-glucuronidase in HepG2 cells. | 2003 Dec |
|
| HNK-1-Reactive oligosaccharide, sulfate-O-3GlcAbeta1-4Xylbeta1-MU, synthesized by cultured human colorectal cancer cells. | 2003 Jan |
|
| A single site in human beta-hexosaminidase A binds both 6-sulfate-groups on hexosamines and the sialic acid moiety of GM2 ganglioside. | 2003 Jan 20 |
|
| Cloning and characterization of two alpha-glucosidases from Bifidobacterium adolescentis DSM20083. | 2003 Mar |
|
| Solid-phase peptide synthesis by ion-paired alpha-chymotrypsin in nonaqueous media. | 2003 Mar 30 |
|
| Physicochemical and saccharide-binding studies on the galactose-specific seed lectin from Trichosanthes cucumerina. | 2003 May 1 |
|
| Pharmacokinetic analysis of factors determining elimination pathways for sulfate and glucuronide metabolites of xenobiotics II: Studies with isolated perfused rat liver. | 2003 Nov |
|
| A nonradioactive 96-well plate assay for screening of trans-sialidase activity. | 2003 Nov 15 |
|
| Structural requirements of hydroxylated coumarins for in vitro anti-Helicobacter pylori activity. | 2003 Sep-Oct |
|
| Identification of aryl-phospho-beta-D-glucosidases in Bacillus subtilis. | 2004 Jan |
|
| Evidence that unsaturated fatty acids are potent inhibitors of renal UDP-glucuronosyltransferases (UGT): kinetic studies using human kidney cortical microsomes and recombinant UGT1A9 and UGT2B7. | 2004 Jan 1 |
|
| Synthesis and biological activity of substituted 2,4,6-s-triazines. | 2004 Mar |
|
| Effects of dietary anticarcinogens and nonsteroidal anti-inflammatory drugs on rat gastrointestinal UDP-glucuronosyltransferases. | 2004 Mar-Apr |
Sample Use Guides
1 tablet 3 times daily during basic meals. The tablets are administered unchewed with a liquid.
Route of Administration:
Oral
4-Methylumbelliferone (4-MU/HYMECROMONE) inhibits hyaluronan synthesis and retards cancer spreading in experimental animals through mechanisms not fully understood. These mechanisms were studied in A2058 melanoma cells, MCF-7 and MDA-MB-361 breast, SKOV-3 ovarian and UT-SCC118 squamous carcinoma cells by analysing hyaluronan synthesis, UDP-glucuronic acid (UDP-GlcUA) content, and hyaluronan synthase (HAS) mRNA levels. The maximal inhibition in hyaluronan synthesis ranged 22-80% in the cell lines tested. Active glucuronidation of 4-MU produced large quantities of 4-MU-glucuronide, depleting the cellular UDP-GlcUA pool. The maximal reduction varied between 38 and 95%. 4-MU also downregulated HAS mRNA levels: HAS3 was 84-60% lower in MDA-MB-361, A2058 and SKOV-3 cells.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 16 16:55:36 UTC 2022
by
admin
on
Fri Dec 16 16:55:36 UTC 2022
|
| Record UNII |
3T5NG4Q468
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
FDA ORPHAN DRUG |
735220
Created by
admin on Fri Dec 16 16:55:36 UTC 2022 , Edited by admin on Fri Dec 16 16:55:36 UTC 2022
|
||
|
WHO-VATC |
QA05AX02
Created by
admin on Fri Dec 16 16:55:36 UTC 2022 , Edited by admin on Fri Dec 16 16:55:36 UTC 2022
|
||
|
FDA ORPHAN DRUG |
732620
Created by
admin on Fri Dec 16 16:55:36 UTC 2022 , Edited by admin on Fri Dec 16 16:55:36 UTC 2022
|
||
|
WHO-ATC |
A05AX02
Created by
admin on Fri Dec 16 16:55:36 UTC 2022 , Edited by admin on Fri Dec 16 16:55:36 UTC 2022
|
||
|
FDA ORPHAN DRUG |
733820
Created by
admin on Fri Dec 16 16:55:36 UTC 2022 , Edited by admin on Fri Dec 16 16:55:36 UTC 2022
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
SUB08089MIG
Created by
admin on Fri Dec 16 16:55:36 UTC 2022 , Edited by admin on Fri Dec 16 16:55:36 UTC 2022
|
PRIMARY | |||
|
C489431
Created by
admin on Fri Dec 16 16:55:36 UTC 2022 , Edited by admin on Fri Dec 16 16:55:36 UTC 2022
|
PRIMARY | |||
|
CHEMBL12208
Created by
admin on Fri Dec 16 16:55:36 UTC 2022 , Edited by admin on Fri Dec 16 16:55:36 UTC 2022
|
PRIMARY | |||
|
90-33-5
Created by
admin on Fri Dec 16 16:55:36 UTC 2022 , Edited by admin on Fri Dec 16 16:55:36 UTC 2022
|
PRIMARY | |||
|
1401
Created by
admin on Fri Dec 16 16:55:36 UTC 2022 , Edited by admin on Fri Dec 16 16:55:36 UTC 2022
|
PRIMARY | |||
|
M6164
Created by
admin on Fri Dec 16 16:55:36 UTC 2022 , Edited by admin on Fri Dec 16 16:55:36 UTC 2022
|
PRIMARY | Merck Index | ||
|
17224
Created by
admin on Fri Dec 16 16:55:36 UTC 2022 , Edited by admin on Fri Dec 16 16:55:36 UTC 2022
|
PRIMARY | |||
|
19026
Created by
admin on Fri Dec 16 16:55:36 UTC 2022 , Edited by admin on Fri Dec 16 16:55:36 UTC 2022
|
PRIMARY | |||
|
DB07118
Created by
admin on Fri Dec 16 16:55:36 UTC 2022 , Edited by admin on Fri Dec 16 16:55:36 UTC 2022
|
PRIMARY | |||
|
201-986-7
Created by
admin on Fri Dec 16 16:55:36 UTC 2022 , Edited by admin on Fri Dec 16 16:55:36 UTC 2022
|
PRIMARY | |||
|
HYMECROMONE
Created by
admin on Fri Dec 16 16:55:36 UTC 2022 , Edited by admin on Fri Dec 16 16:55:36 UTC 2022
|
PRIMARY | |||
|
5556
Created by
admin on Fri Dec 16 16:55:36 UTC 2022 , Edited by admin on Fri Dec 16 16:55:36 UTC 2022
|
PRIMARY | RxNorm | ||
|
3T5NG4Q468
Created by
admin on Fri Dec 16 16:55:36 UTC 2022 , Edited by admin on Fri Dec 16 16:55:36 UTC 2022
|
PRIMARY | |||
|
9408
Created by
admin on Fri Dec 16 16:55:36 UTC 2022 , Edited by admin on Fri Dec 16 16:55:36 UTC 2022
|
PRIMARY | |||
|
1891
Created by
admin on Fri Dec 16 16:55:36 UTC 2022 , Edited by admin on Fri Dec 16 16:55:36 UTC 2022
|
PRIMARY | |||
|
C166696
Created by
admin on Fri Dec 16 16:55:36 UTC 2022 , Edited by admin on Fri Dec 16 16:55:36 UTC 2022
|
PRIMARY | |||
|
D006923
Created by
admin on Fri Dec 16 16:55:36 UTC 2022 , Edited by admin on Fri Dec 16 16:55:36 UTC 2022
|
PRIMARY | |||
|
5280567
Created by
admin on Fri Dec 16 16:55:36 UTC 2022 , Edited by admin on Fri Dec 16 16:55:36 UTC 2022
|
PRIMARY | |||
|
DTXSID8025670
Created by
admin on Fri Dec 16 16:55:36 UTC 2022 , Edited by admin on Fri Dec 16 16:55:36 UTC 2022
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
SALT/SOLVATE -> PARENT | |||
|
SOLVATE->ANHYDROUS | |||
|
|
SALT/SOLVATE -> PARENT |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
